Central Diabetes Insipidus – An Uncommon Presentation of Acute Myeloid Leukaemia: A Case Report and Literature Review
Pavitra D. S. *
Department of Clinical Haematology, Haemato-Oncology & Bone Marrow (Stem Cell) Transplantation, Christian Medical College, Ludhiana, India.
Jason Jacob
Department of Endocrinology, Christian Medical College, Ludhiana, India.
Poojitha Byreddy
Department of Clinical Haematology, Haemato-Oncology & Bone Marrow (Stem Cell) Transplantation, Christian Medical College, Ludhiana, India.
Jubbin Jacob
Department of Endocrinology, Christian Medical College, Ludhiana, India.
Naveen Samuel
Department of Endocrinology, Christian Medical College, Ludhiana, India.
M. Joseph John
Department of Clinical Haematology, Haemato-Oncology & Bone Marrow (Stem Cell) Transplantation, Christian Medical College, Ludhiana, India.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Central diabetes insipidus (CDI) is a rare manifestation of Acute myeloid leukaemia (AML). Patients can present with polyuria, polydipsia, weight loss and electrolyte disturbances either at the time of diagnosis or while on treatment. Due to the underlying haematological malignancy, management of this condition might become challenging.
Case Summary: We report a 65-year-old gentleman diagnosed with acute myeloid leukaemia. Post 2 cycles of azacytidine therapy, he presented with polyuria, polydipsia and weight loss.
On evaluation, he was diagnosed with CDI after performing water deprivation test and correlating biochemical parameters. Concurrent MRI of the brain showed well defined homogeneously enhancing posterior pituitary lesions suggestive of leukemic deposits confirming the diagnosis of CDI.
Diagnosis of diabetes insipidus (DI) was made 2 months after the diagnosis of AML. The patient was started on oral desmopressin at a dose of 0.2 mg per day. Upon initiation of the therapy there was significant relief of symptoms. He was simultaneously continued on therapy with hypomethylating agent (Azacytidine) and Venetoclax for AML. Upon initiation of therapy, the symptoms significantly subsided. He continued receiving treatment for AML with Venetoclax and azacytidine. However, the patient succumbed to the disease 9 months post the diagnosis of CDI.
Conclusion: AML- M4/M5 with monocytic differentiation have a propensity to invade various extramedullary tissues, including the skin, gingiva, brain, and endocrine organs. If patients with AML present with symptoms of increased urination, excessive thirst, and weight loss, it is crucial to consider the possibility of CDI and conduct a thorough assessment for this condition.
Keywords: Acute myeloid leukaemia, central diabetes insipidus, water deprivation test, desmopressin
How to Cite
Downloads
References
Lakshmanan P, Asnani H, Knorr D. Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation. Case Rep Endocrinol. 2022;2022.
Garrahy A, Moran C, Thompson CJ. Diagnosis and management of central diabetes insipidus in adults. Clin Endocrinol (Oxf). 2019 Jan 1;90(1):23–30.
Müller CI, Engelhardt M, Laubenberger J, Kunzmann R, Engelhardt R, Lübbert M. Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7. Eur J Haematol. 2002 Aug;69(2):115–9.
Dy P, Chua P, Kelly J, Liebman S. Central diabetes insipidus in the setting of acute myelogenous leukemia. Am J Kidney Dis. 2012 Dec;60(6):998–1001.
Ladigan S, Mika T, Figge A, May AM, Schmiegel W, Schroers R, et al. Acute myeloid leukemia with central diabetes insipidus. Blood Cells Mol Dis. 2019 May 1;76:45–52.
Ra'anani P, Shpilberg O, Berezin M, Ben‐Bassat I. Acute leukemia relapse presenting as central diabetes insipidus. Cancer. 1994 May 1;73(9):2312-6.
Loukidis K, Papadakis E, Anagnostou N, Kiriklidou P, Gatsa E, Karagianni A, Patinakis P, Tsakiris D, Kioumi A, Korantzis I. Polyuria due to central diabetes insipidus presenting as an early manifestation of acute myeloid leukemia. Clin Adv Hematol Oncol. 2012 Jun 1;10(6):399-400
Pritzl SL, Matson DR, Juckett MB, Ciske DJ. Concurrent Central Diabetes Insipidus and Acute Myeloid Leukemia. Case Rep Hematol. 2021 Feb 16;2021:1–5.
Miller VI, Campbell WG. Diabetes insipidus as a complication of leukemia: A case report with a literature review. Cancer. 1971;28(3):666–73.
Sonmez M, Erkut N, Tat TS, Celep F, Cobanoglu U, Ersoz HO. Can a high platelet count be responsible for diabetes insipidus in acute myelogenous leukemia with monosomy 7 and inversion 3 (q21q26)? Int J Hematol. 2009 Sep;90(2):273–4.
Cull EH, Watts JM, Tallman MS, Kopp P, Frattini M, Rapaport F, et al. Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: A case series with molecular genetic analysis and review of the literature. Leuk Lymphoma. 2014;55(9):2125–9.
Yang Y, Lin T, Dong T, Wu Y. Myelodysplastic syndrome presenting with central diabetes insipidus is associated with monosomy 7, visible or hidden: report of two cases and literature review. Mol Cytogenet. 2021 Dec;14(1):42.
Harrup R, Pham M, McInerney G. Acute myeloid leukemia with diabetes insipidus and hypophyseal infiltration. Asia Pac J Clin Oncol. 2016 Jun 1;12(2):e350–1.